Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

doi:10.3322/caac.20061

Review

. 2010 May-Jun;60(3):194-201.

doi: 10.3322/caac.20061. Epub 2010 Feb 2.

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

Glenn N Levine¹, Anthony V D'Amico, Peter Berger, Peter E Clark, Robert H Eckel, Nancy L Keating, Richard V Milani, Arthur I Sagalowsky, Matthew R Smith, Neil Zakai; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association

Affiliations

PMID: 20124400
PMCID: PMC3049943
DOI: 10.3322/caac.20061

Review

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

Glenn N Levine et al. CA Cancer J Clin. 2010 May-Jun.

. 2010 May-Jun;60(3):194-201.

doi: 10.3322/caac.20061. Epub 2010 Feb 2.

Authors

Affiliation

¹ Michael E. DeBakey Veteran's Affairs Medical Center, Houston, TX, USA. glenn.levine@bcm.tmc.edu

PMID: 20124400
PMCID: PMC3049943
DOI: 10.3322/caac.20061

No abstract available

PubMed Disclaimer

Cited by

[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
Klemm J, von Deimling M, Fisch M, Kramer G, Tilki D, Steuber T, von Amsberg G, Hengstenberg C, Shariat SF. Klemm J, et al. Urologie. 2024 Mar;63(3):262-268. doi: 10.1007/s00120-023-02222-1. Epub 2023 Oct 24. Urologie. 2024. PMID: 37874334 Review. German.
Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.
Yan Z, Xu Y, Li K, Liu L. Yan Z, et al. Medicine (Baltimore). 2023 Sep 29;102(39):e34690. doi: 10.1097/MD.0000000000034690. Medicine (Baltimore). 2023. PMID: 37773823 Free PMC article.
An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China.
Chen L, Lu F, Wang Z, Chen H, Chen M, Peng C, Chen K, Chen C, Xiong H, Xie X. Chen L, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2225389. doi: 10.1080/21645515.2023.2225389. Epub 2023 Jun 23. Hum Vaccin Immunother. 2023. PMID: 37350143 Free PMC article.
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
Braga-Basaria M, Travison TG, Taplin ME, Lin A, Dufour AB, Habtemariam D, Nguyen PL, Kibel AS, Ravi P, Bearup R, Kackley H, Kafel H, Reid K, Storer T, Simonson DC, McDonnell M, Basaria S. Braga-Basaria M, et al. PLoS One. 2023 Feb 10;18(2):e0281508. doi: 10.1371/journal.pone.0281508. eCollection 2023. PLoS One. 2023. PMID: 36763576 Free PMC article.
Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China.
Zhang F, Li M, Li X, Bai H, Gao J, Liu H. Zhang F, et al. BMC Public Health. 2022 Dec 5;22(1):2269. doi: 10.1186/s12889-022-14718-0. BMC Public Health. 2022. PMID: 36471351 Free PMC article.

See all "Cited by" articles

References

1. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456. - PubMed
1. Saigal CS, Gore JL, Krupski TL, et al. the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500. - PubMed
1. D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425. - PubMed
1. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524. - PubMed
1. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290–3297. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456. - PubMed

[2] Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456. - PubMed

[3] Saigal CS, Gore JL, Krupski TL, et al. the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500. - PubMed

[4] Saigal CS, Gore JL, Krupski TL, et al. the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500. - PubMed

[5] D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425. - PubMed

[6] D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425. - PubMed

[7] Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524. - PubMed

[8] Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524. - PubMed

[9] D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290–3297. - PubMed

[10] D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290–3297. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

Affiliation

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

Authors

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical